Metoclopramide Injection Solution and Safinamide Mesylate
Determining the interaction of Metoclopramide Injection Solution and Safinamide Mesylate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using metoclopramide together with safinamide may occasionally cause high blood pressure and high fever. It may be preferable to wait at least 14 days after you are off safinamide before you start using metoclopramide. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you experience sudden and severe headache, blurred vision, confusion, seizures, chest pain, nausea or vomiting, sudden numbness or weakness (especially on one side of the body), speech difficulties, fever, sweating, lightheadedness, and/or fainting during treatment with these medications, as these may be signs and symptoms of excessively high blood pressure. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Theoretically, metoclopramide may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). Metoclopramide has been shown to induce the release of catecholamines in patients with essential hypertension. This action could produce a synergistic sympathomimetic effect with MAOIs, which enhance norepinephrine storage in adrenergic neurons.
MANAGEMENT: While clinical data are lacking, metoclopramide should preferably not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with metoclopramide.
- "Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
- Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984): 548-9
Generic Name: metoclopramide
Brand name: Metozolv ODT, Reglan
Synonyms: Metoclopramide
Generic Name: safinamide
Brand name: Xadago
Synonyms: Safinamide
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Metoclopramide Injection Solution-Safyral
- Metoclopramide Injection Solution-Saizen
- Metoclopramide Injection Solution-Saizen Subcutaneous, Injection
- Metoclopramide Injection Solution-Sal-Acid Plaster Topical
- Metoclopramide Injection Solution-Sal-Plant
- Metoclopramide Injection Solution-Sal-Plant Gel Topical
- Safinamide Mesylate-Metoclopramide Intravenous
- Safinamide Mesylate-Metoclopramide Oral Solution
- Safinamide Mesylate-Metoclopramide oral/injection
- Safinamide Mesylate-Metoclopramide Orally Disintegrating Tablets
- Safinamide Mesylate-Metoclopramide Tablets
- Safinamide Mesylate-Metolazone